Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models

Clinical Cancer Research

Volumn 9, Issue 11, 2003, Pages 4227-4239

  Voskoglou Nomikos, Theodora ^a   Pater, Joseph L ^a   Seymour, Lesley ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLOROSULFAQUINOXALINE; AMONAFIDE; ASULACRINE ISETHIONATE; CYTOTOXIC AGENT; DIDEMNIN B; DOCETAXEL; ELSAMICIN A; EPIRUBICIN; FAZARABINE; FOSQUIDONE; FOTEMUSTINE; GEMCITABINE; ILMOFOSINE; IRINOTECAN; LOSOXANTRONE; MENOGARIL; MITOFLAXONE; MIVOBULIN ISETHIONATE; NAVELBINE; PACLITAXEL; PIRITREXIM; PYRAZINE DIAZOHYDROXIDE; RALTITREXED; RHIZOXIN; SURAMIN; TENIPOSIDE; TIAZOFURIN; TOPOTECAN; TRIMETREXATE; UNINDEXED DRUG;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RELIABILITY; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASMS, EXPERIMENTAL; PREDICTIVE VALUE OF TESTS; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0141566685     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Curt, G. A. The use of animal models in cancer drug discovery and development. Stem Cells, 12: 23-29, 1994.
2. Goldin, A., Serpick, A. A., and Mantel, N. Experimental screening procedures and clinical predictability value. Cancer Chemother. Rep., 50: 173-218, 1966.
3. Venditti, J. M. Drug evaluation branch program: report to screening contractors. Cancer Chemother. Rep., 5: 1-4, 1975.
4. Venditti, J. M. Preclinical drug development: rationale and methods. Semin. Oncol., 8: 349-353, 1981.
5. Venditti, J. M., Wesley, R. A., and Plowman, J. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982 and future directions. Adv. Pharmacol. Chemother., 20: 1-19, 1984.
6. Venditti, J. M. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary. Cancer Treat. Rep., 67: 767-772, 1983.
7. Staquet, M. J., Byar, D. P., Green, S. B., and Rozencweig, M. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat. Rep., 67: 753-765, 1983.
8. Goldin, A., Venditti, J. M., MacDonald, J. S., Muggia, F. M., Henney, J. E., and De Vita V. T. Current results of the screening program at the division of cancer treatment, National Cancer Institute. Eur. J. Cancer, 17: 129-142, 1981.
9. Marsoni, S., and Wittes, R. Clinical development of anticancer agents: A National Cancer Institute perspective. Cancer Treat. Rep., 68: 77-85, 1983.
10. De Vita, V. T., and Schein, P. S. The use of drugs in combination for the treatment of cancer N. Engl. J. Med., 288: 998-1006, 1973.
11. Zubrod, C. G. Chemical control of cancer. Proc. Natl. Acad. Sci. USA, 69: 1042-1047, 1972.
12. Marsoni, S., Hoth, D., Simon, R., Leyland-Jones, B., De Rosa, M., and Wittes, R. E. Clinical drug development: an analysis of Phase II trials, 1970-1985. Cancer Treat. Rep., 71: 71-80, 1987.
13. Shoemaker, R. H., Monks, A., Alley, M. C., Scudiero, D. A., Fine, D. L., McLemore, T. L., Abbott, B. J., Paull, K. D., Mayo, J. G., and Boyd, M. R. Development of human tumor cell line panels for use in disease-oriented drug screening. Prog. Clin. Biol. Res., 276: 265-286, 1988.
14. Skehan, P., Storeng, R., Scudiero, D., Monks A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer drug screening. J. Natl. Cancer Inst. (Bethesda), 82: 1107-1112, 1990.
15. Rubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D., Monks, A., and Boyd, M. R. Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. (Bethesda), 82: 1113-1118, 1990.
16. Alley, M. C., Scudiero, D., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. Feasibility of drug screening with panels of human tumor Cell lines using a microculture tetrazolium assay. Cancer Res., 48: 589-601, 1988.
17. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R. H., Paull, K. D., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Mayo, J., and Boyd, M. R. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. (Bethesda), 83: 757-766, 1990.
18. Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christin, M., Arbuck, S., Hollingshead, M., and Sausville, E. A. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer, 84: 1424-1431, 2001.
19. Bellet, R. E., Danna, V., Mastrangelo, M. J., and Berd, D. Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapy agents. J. Natl. Cancer Inst. (Bethesda), 63: 1185-1187, 1979.
20. Bailey, M. J., Gazet, J-C., Smith, I. E., and Steel, G. G. Chemotherapy of human breast-carcinoma xenografts. Br. J. Cancer, 42: 530-536, 1980.
21. Inoue, K., Fujimote, S., and Ogawa, M. Antitumor efficacy of seventeen anticancer drugs in human breast cancer xenograft (MX-1) transplanted in nude mice. Cancer Chemother. Pharmacol., 10: 182-186, 1983.
22. Steel, G. G., Courtenay, V. D., and Peckhan M. J. The response to chemotherapy of a variety of human tumor xenografts. Br. J. Cancer, 47: 1-13, 1983.
23. Taetle, R., Rosen, F., Abramson, I., Venditti, J., and Howell, S. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat. Rep., 71: 297-304, 1987.
24. Mattern, J., Bak, M., Hahn, E. W., and Volm, M. Human tumor xenografts as models for drug testing. Cancer Metastasis Rev., 7: 263-284, 1988.
25. Boven, E., Winograd, B., Fodstad, O., Lobbezzoo, M. W., and Pinedo, H. M. Preclinical Phase II studies in human tumor lines: a European multicenter study. Eur. J. Cancer, 24: 567-573, 1988.
26. Boven, E., Winograd, B., Berger, D. P., Dumant, M. P., Braakhuis, B. J. M., Fodstad, O., Langdon, S., and Fiebig, H. H. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res., 52: 5940-5947, 1992.
27. Langdon, S., Hendriks, H. R., Braakhuis, B. J. M., Pratesi, G., Berger, D. P., Fodstad, O., Fiebig, H., and Boven, E. Preclinical Phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann. Oncol., 5: 415-422, 1994.
28. Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D., Rubinstein, L. V., Plowman, J., and Boyd, M. R. Display and analysis of patterns of differential activities of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. (Bethesda), 81: 1088-1092, 1989.
29. Rosner, B. Non-parametric Methods. In: Fundamentals of Biostatistics, 4th ed., p. 575. Belmont, CA: Duxbury Press, Wadsworth Publishing Company, 1994.
30. Kolfscoten, G. M., Pinedo, H. M., Scheffer, P. G., Schluper, H. M. M., Erkelens, C. A. M., and Boven, E. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Gynecol. Oncol., 76: 362-368, 2000.
31. Louie, A. C., and Issell, B. F. Amsacrine (AMSA): a clinical review. J. Clin. Oncol., 3: 562-592, 1985.
32. Minna, J. D., Pass, H., Glatsein, E., and Inde, D. Cancer of the lung. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer Principles and Practice of Oncology, pp. 660 (Table 22-48). Philadelphia: J. B. Lippincott, 1989.
33. Gordon, A. N., Granai, C. O., Rose, P. G., Hainsworth, J., Lopez, A., Weissman, C., Rosales, R., and Sharpington, T. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. Clin. Oncol., 18: 3093-3100, 2000.
34. Israel, V. P., Garcia, A. A., Roman, L., Muderspach, L., Burnett, A., Jeffers, S., and Muggia, F. M. Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol. Oncol., 78: 143-147, 2000.
35. Muggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., Burnett, A., Greco, F. A., Morrow, C. P., Paradiso, L. J., and Liang, L. J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol., 15: 987-993, 1997.
36. Blum, R. H., and Carter, S. K. Adriamycin: a new anticancer drug with significant clinical activity. Ann. Intern. Med., 80: 249-259, 1974.
37. Thigpen, J. T., Lagasse, L., Homesley, H., and Blessing, J. A. Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Phase II study of the Gynecology Oncology Group. Am. J. Clin. Oncol., 6: 431-435, 1983.
38. Wiltshaw, E., and Kroner, T. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat. Rep., 60: 55-60, 1976.
39. Bonomi, P. D., Mladineo, J., Morrin, B., Wilbanks, G., Jr., and Slayton, R. E. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents. Cancer Treat. Rep., 63: 137-138, 1979.
40. Johnson, B. L., Fisher, R. I., Bender, R. A., DeVita, V. T., Jr., Chabner, B. A., and Young, R. C. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. Cancer (Phila.), 42: 2157-2161, 1978.
41. Omura, G. A., Blessing, J. A., Morrow, C. P., Buchsbaum, H. J., and Homesley, H. D. Follow-up on a randomized trial of melphalan (M) vs. melphalan plus hexamethylamine (M+H) versus Adriamycin plus cyclophosphamide (A+C) in advanced ovarian carcinoma. Proc. Am. Assoc. Cancer Res., 22: 470, 1981.
42. Bolis, G., D'Incalci, M., Belloni, C., and Mangioni, C. Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and Adriamycin. Cancer Treat. Rep., 63: 1375-1377, 1979.
43. Manetta, A., MacNeill, C., Lyter, J. A., Scheffler, B., Podczaski, E. S., Larson, J. E., and Schein, P. Hexamethylmelamine as a single second-line agent in ovarian cancer. Gynecol. Oncol., 36: 93-96, 1990.
44. Rosen, G. F., Lurain, J. R., and Newton, M. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy. Gynecol. Oncol., 27: 173-179, 1987.
45. Parker, L. M., Griffiths, C. T., Yankee, R. A., Knapp, R. C., and Canellos, G. P. High-dose methotrexate with leucovorin rescue in ovarian cancer: a Phase II study. Cancer Treat. Rep., 63: 275-279, 1979.
46. Barlow, J. J., and Piver, M. S. Methotrexate (NSC-740) with citrovorum factor (NSC-3590) rescue, alone and in combination with cyclophosphamide (NSC-26271), in ovarian cancer. Cancer Treat. Rep., 60: 527-533, 1976.
47. Morgan, R. J., Jr., Speyer, J., Doroshow, J. H., Margolin, K., Raschko, J., Sorich, J., Akman, S., Leong, L., Somlo, G., and Vasilev, S. Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels. Gynecol. Oncol., 58: 79-85, 1995.
48. Markman, M., Reichman, B., Hakes, T., Hoskins, W., Rubin, S., Jones, W., and Lewis, J. L., Jr. Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience). Acta Med. Austriaca, 16: 65-67, 1989.
49. Prefontaine, M., Donovan, J. T., Powell, J. L., and Buley, L. Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin. Gynecol. Oncol., 61: 249-252, 1996.
50. Kamphuis, J. T., Huider, M. C., Ras, G. J., Verhagen, C. A., Kateman, I., Vreeswijk, J. H., and Burghouts, J. T. High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer. Cancer Chemother. Pharmacol., 37: 190-192, 1995.
51. Burnett, A. F., Barter, J. F., Potkul, R. K., Jarvis, T., and Barnes, W. A. Ineffectiveness of continuous 5-fluorouracil as salvage therapy for ovarian cancer. Am. J. Clin. Oncol., 17: 490-493, 1994.
52. Reed, E., Jacob, J., Ozols, R. F., Young, R. C., and Allegra, C. 5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma. Gynecol. Oncol., 46: 326-329, 1992.
53. Ozols, R. F., Speyer, J. L., Jenkins, J., and Myers, C. E. Phase II trial of 5-FU administered Ip to patients with refractory ovarian cancer. Cancer Treat. Rep., 68: 1229-1232, 1984.
54. Long, H. J., III, Nelimark, R. A., Su, J. Q., Garneau, S. C., Levitt, R., Goldberg, R. M., Poon, M. A., and Kugler, J. W. Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma. Gynecol. Oncol., 54: 180-183, 1994.
55. Look, K. Y., Muss, H. B., Blessing, J. A., and Morris, M. A. Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecology Oncology Group Study. Am. J. Clin. Oncol., 18: 19-22, 1995.
56. De Graeff, A., van Hoef, M. E., Tjia, P., Heintz, A. P., and Neijt, J. P. Continuous infusion of 5-fluorouracil in ovarian cancer patients refractory to cisplatin and carboplatin. Ann. Oncol., 2: 691-692, 1991.
57. Volpe, D. A., Tomaszewski, J. E., Parchment, R. E., Garg, A., Flora, K. P., Murphy, M. J., and Grieshaber, C. K. Myelotoxic effects of the bifunctional alkylating agent bizelesin in human, canine and murine myeloid progenitor cells. Cancer Chemother. Pharmacol., 39: 143, 1996.
58. Gelmon, K. A., Eisenhauer, E. A., Harris, A. L., Ratain, M. J., and Workman, P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J. Natl. Cancer Inst. (Bethesda), 91: 1281-1287, 1999.
59. Killion, J. J., Radinsky, R., and Fidler, I. J. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev., 17: 279-284, 1999.
60. Kerbel, R. S. What is the optimal rodent model for anti-tumor drug testing? Cancer Metastasis Rev., 17: 301-304, 1999.
61. Rosenberg, M. P., and Bortner, D. Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer). Cancer Metastasis Rev., 17: 295-299, 1999.